Merck acquires Peloton Therapeutics for $1 billion
The acquisition of Peloton, which was seeking to go public last week, brings its lead kidney cancer drug candidate to Merck, strengthening its renal cell carcinoma presence
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Merck | Mergers and Aquisitions | Pharmaceuticals | Renal Cell Carcinoma | Urology & Nephrology